Clinical efficacy analysis of edaravone combined with urinary tract infection in the treat-ment of acute cerebral infarction
Objective To explore the clinical efficacy of edaravone combined with urinary tract infections in the treatment of acute cerebral infarction.Method 84 patients with acute cerebral infarction at Shangyu People's Hospital in Shaoxing City,Zhejiang Province from October 2020 to October 2023 were randomly divided into two groups:the edaravone group and the combination therapy group,with 42 patients in each group.On the basis of symptomatic treatment(antiplatelet coagulation,microcirculation regulation,etc.),the two groups received intravenous infusion of 30mg of edaravone dissolved in 250mL 0.9％NaCl injection in the edaravone group;On the basis of the edaravone group,the combination of human urinary tract infection and human urinary tract infection was diluted with 0.15 PNA units of human urinary tract infection in 100mL 0.9％NaCl injection each time,and then intravenously dripped for 30 minutes.After 14 days of treatment,the efficacy,NIHSS score,recovery status(mRS scale),daily living ability(BI),cognitive function(MoCA scale),hemorheological indica-tors(whole blood high and low shear viscosity,plasma viscosity,platelet aggregation rate,hematocrit),cytokines(VE cad-herin,MCP-1,NSE),and adverse reactions during treatment were compared between the two groups.Results The total ef-fective rate(90.48％)of the combination therapy group with urinary tract infection was higher than that of the edaravone group(71.43％)(P＜0.05).Compared with before treatment,after 14 days of treatment,the mRS score,NIHSS score,hemorhe-ological indicators,and cytokines in the combination therapy group were lower than those in the edaravone group(P＜0.05),while the BI and MoCA scores were higher than those in the edaravone group(P＜0.05);During the treatment period,there was no statistically significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion The combination of Urinary Kallidinogenase and Edaravone in the treatment of acute cerebral infarction can effectively re-duce inflammatory response,regulate related factor levels and hemorheological indicators,improve patients'neurological and cognitive function,enhance daily living ability,and have good efficacy and safety.
NETL
NSTL
万方数据
